Full-Time

Associate Scientist

Compound Management, Cell Screening & NGS

Korro Bio

Korro Bio

51-200 employees

RNA editing-based therapeutics discovery and development

Compensation Overview

$84k - $112k/yr

+ Equity-based compensation

Cambridge, MA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Master's degree with 2+ years of experience in an industrial or academic laboratory setting or Bachelor's degree with 4+ years' experience or equivalent industry experience.
  • Experience with nucleic acids and analytical chemistry with UV spectrophotometry, HPLC, and LCMS analysis.
  • Deep familiarity with oligonucleotide chemistry, including synthesis, handling, and physicochemical characterization of modified nucleic acids.
  • Demonstrated ability to manage high-volume compound inventories with rigorous attention to sample integrity and traceability.
  • Hands-on experience operating and programming automated liquid handlers, with a strong preference for Hamilton STAR or Vantage platforms; experience writing or modifying Hamilton methods (Venus/Venus One) is highly desirable.
  • Comfort troubleshooting liquid handling errors, calibrating channels, and optimizing pipetting parameters for low-volume or viscous nucleic acid samples.
  • Experience with ddPCR for nucleic acid quantification; familiarity with multiplexed ddPCR assay design a plus.
  • Experience with LIMS systems, ELN, and workflow/scheduling software a plus.
  • Exposure to cell-based assays, NGS library preparation, or sequencing platforms is a plus, though not a primary focus of the role.
  • High attention to detail with the ability to handle large sets of compounds accurately.
  • High degree of flexibility and self-motivation in a fast-paced work environment, ability to prioritize appropriately and meet deadlines.
  • Excellent interpersonal, communication and presentation skills.
Responsibilities
  • Oligonucleotide compound management and preparation of samples for biological screening, including via automated liquid handling platforms.
  • Analysis and formulation of test articles for in vitro and in vivo studies.
  • Receive, track, and maintain physical and virtual inventory of test articles, formulations, and components.
  • Manage and coordinate large oligonucleotide compound sets across multiple concurrent projects, ensuring accurate sample identity, concentration, and availability to meet screening timelines.
  • Serve as the primary point of contact for compound logistics, including reformatting, normalization, and distribution to downstream assay and in vivo teams — executed primarily through automated liquid handling workflows.
  • Operate, maintain, and troubleshoot automated liquid handling systems (e.g., Hamilton STAR/Vantage, Tecan, Viaflo96/384, Tempest) for high-throughput compound preparation, serial dilution, plate reformatting, and sample distribution.
  • Quantification of oligonucleotide compounds and formulated complexes via Mass Spec and UV spectrophotometry.
  • Employ ddPCR for absolute quantification of nucleic acid compounds and edited targets, supporting both compound QC and downstream analytical readouts.
  • Purity analysis via analytical HPLC and LCMS, ability to troubleshoot and develop methods on analytical systems.
  • Support cell-based screening and NGS workflows as needed, including high-throughput assay preparation, ddPCR-based QC, library preparation, and operation of sequencing platforms (e.g., Illumina MiSeq), in a collaborative capacity.
  • Maintain a well-documented electronic/laboratory notebook.

Korro Bio develops RNA-based therapies using RNA editing to modify protein function, aiming to treat serious diseases with few or no current options. The approach targets RNA itself, enabling single base edits in transcripts to change how proteins work, which can adjust disease pathways without altering the DNA. These therapies are intended to be developed and brought to market through direct development or partnerships, with revenue coming from therapy sales, licensing, and collaborations. The company focuses on research and development to translate human genetics insights into treatments, working with healthcare providers, patients, and academic partners. Overall, Korro Bio seeks to move RNA editing toward real therapies that can help patients around the world by offering precise, targeted interventions at the RNA level.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • $85M PIPE in 2025 extends cash runway through H2 2028.
  • Novo Nordisk partnership develops cardiometabolic candidates since Sept 2024.
  • KRRO-121 advances for urea cycle disorders and hepatic encephalopathy.

What critics are saying

  • KRRO-110 trial failed functional protein levels, causing 80% stock drop.
  • Beam Therapeutics' base editing outpaces Korro in AATD liver delivery.
  • Intellia CRISPR AATD enters Phase 1 with 50% NHP protein correction.

What makes Korro Bio unique

  • OPERA platform co-opts endogenous ADAR for precise single-base RNA edits.
  • CHORD oligonucleotides enable high specificity without off-target DNA risks.
  • Targets liver diseases like AATD using precedented manufacturing and delivery.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Korro Bio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

10%

2 year growth

12%
Maeil Business Newspaper
Mar 9th, 2026
Korro Bio raises $85M PIPE to fund operations through H2 2028

Korro Bio has raised $85 million through a private investment in public equity (PIPE) round led by new investor Bainrock Healthcare Capital Partners. The company issued 4.5 million ordinary shares at $11.11 per share and 3.1 million pre-funded warrants at $11.109 per share. Combined with $85.2 million in cash and cash equivalents as of 31 December 2025, the funding extends Korro Bio's cash runway through the second half of 2028. The capital will accelerate development of its RNA editing platform OPERA, including clinical programmes KRRO-121 and a GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency. Citigroup, Cantor, Oppenheimer and William Blair served as placement agents. Analysts forecast continued losses through 2027 despite projected revenue growth.

Investing.com
Mar 9th, 2026
Korro Bio raises $85 million in private equity financing By Investing.com

Korro Bio raises $85 million in private equity financing

Stock Titan
Jan 7th, 2025
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro to present at the 43rd Annual J.P. Morgan Healthcare Conference.

Investing.com
Oct 16th, 2024
KRRO stock soars to 52-week high, touches $98 amid robust gains

In other recent news, Korro Bio has announced a strategic partnership with Novo Nordisk (NYSE:NVO), a global healthcare company, to develop genetic medicines for cardiometabolic diseases.

BioSpace
Sep 16th, 2024
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

Korro Bio announces collaboration with Novo Nordisk to develop two therapeutic candidates.